(TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback